Project PRIORITY is a patient-founded and patient-driven research partnership between the EGFR Resisters and LUNGevity Foundation. This specific part of the study was presented as a poster in WCLC 2020 and focuses on palliative care and prognostic awareness perceptions.
We are a group of lung cancer patients with EGFR mutations who have developed resistance to at least one targeted treatment drug, or who face probable resistance in the future. Caregivers are also welcome. We are here to share treatment experiences, information about clinical trials, breaking news about research developments, and other information with each other.